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Abstract 
Background: Anaphylaxis during anaesthesia is important for patients and anaesthetists.  
Method: The 6
th
 National Audit Project of the Royal College of Anaesthetists examined the 
incidence, predisposing factors, management and impact of life-threatening perioperative 
anaphylaxis. NAP6 included: a national survey of anaesthetists' experiences and perceptions; a 
national survey of allergy clinics; a registry collecting detailed reports of all Grade 3-5 perioperative 
anaphylaxis cases for one year; and a national survey of anaesthetic workload and perioperative 
allergen exposure. National Health Service (NHS) and independent sector (IS) hospitals were 
approached to participate. Cases were reviewed by a multi-disciplinary expert panel (anaesthetists, 
intensivists, allergists, immunologists, patient representatives and stakeholders) using a structured 
process designed to minimise bias. Clinical management and investigation were compared with 
published guidelines. This paper describes detailed study methods and reports on project 
engagement by NHS and IS hospitals. The methodology includes a new classification of perioperative 
anaphylaxis and a new structured method for classifying suspected anaphylactic events and the 
degree of certainty with which a causal trigger agent can be attributed. 
Results: NHS engagement was complet  (100% of hospitals). Independent sector engagement was 
limited (13% of approached hospitals). We received >500 reports of Grade 3-5 perioperative 
anaphylaxis, with 266 suitable for analysis. We identified 199 definite or probable culprit agents. 
Antibiotics (47%) were the most common cause of perioperative anaphylaxis, followed by 
neuromuscular blocking agents (33%); chlorhexidine (9%) and patent blue dye (4.5%). Latex 
anaphylaxis was not reported.  
Conclusions: The methods of NAP6 are robust and support the accompanying papers.  
 
 
 
Keywords: anaphylaxis; anaesthesia; allergy; National Audit Project 
 
 
Page 4 of 28British Journal of Anaesthesia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
 
Life-threatening allergy during anaesthesia and surgery (perioperative anaphylaxis) is a subject of 
importance to both patients and clinicians.
1
 Importance relates to the impact on patient safety and 
in relation to specific subsets of patients or drugs.
1
  
 
A number of factors mean that data from historical studies or from other geographical locations may 
not be transferrable to current practice or UK practice. No major prospective study of perioperative 
anaphylaxis has been performed in the UK. 
 
The National Audit Projects of the Royal College of Anaesthetists have an established role in 
examining clinically important, rare complications of anaesthesia that are incompletely studied.
2-7
 
The established methodology of the NAPs is to perform a national survey or surveys of relevant 
national activity
8,9 
and establish a national registry for reporting of relevant cases for a time-limited 
period. This enables an examination of (a) pre-existing practices and beliefs (b) relevant activity 
(denominator data) and (c) a large cohort of relevant cases (numerator data) and thence (d) 
incidence data. 
 
Methods 
The 6th National Audit Project (NAP6) was commissioned by the Health Services Research Centre 
(HSRC) of the National Institute of Academic Anaesthesia for the Royal College of Anaesthetists 
(RCoA). It is the sixth in a series of ‘national audits’ (though more correctly described as service 
evaluations) conducted by the specialty.
10
.  
 
The topic for NAP6 was selected by open tender for proposals in 2013. There were 91 proposals 
covering 33 topics.
11
 The topic of perioperative anaphylaxis was selected by a committee comprised 
of members of the HSRC executive board.  
 
The intention of the project was to establish  
 What proportion of cases of suspected perioperative anaphylaxis is referred and or investigated? 
 What proportion of investigated cases is proven or unproven? 
 How well does management, referral and investigation match published guidelines? 
 Is there any correlation between drugs used in resuscitation, e.g., adrenaline, alpha agonists 
vasopressin and outcome for severe cases? 
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The methodology of NAP6 is similar to, and builds upon, that used for NAP3-5.
2,3,5 
 
The NAP6 project was approved by Confidentiality Advisory Committee of the NHS Health Research 
Authority (HRA), National and Local Caldicott Scrutiny Process in Scotland and Privacy Advisory 
Committee for Northern Ireland. The Confidential Advisory Committee deals with approvals for the 
handling of patient-identifiable information across the NHS. If such information is required, then 
approvals are required under Section 251 of its governance procedures. Since no patient-identifiable 
information was used, no section 251 application was necessary. The National Research Ethics 
Service (NRES) confirmed it to be a service evaluation, not requiring formal ethical approval. The 
project received the endorsement of all four Chief Medical Officers of the UK.  
 
All hospitals in the UK performing surgical procedures with anaesthetist involvement were 
contacted. This included 356 UK National Health Service hospital centres and 304 Independent 
Sector hospitals believed to perform surgical work. All NHS centres volunteered a Local Co-ordinator 
(LC), a consultant anaesthetist who became responsible for delivering the project at their hospital 
and for liaising with the central NAP6 team. Several LCs were responsible for more than one hospital 
within a Trust (England, Northern Ireland) or Board (Scotland, Wales). During efforts to engage with 
the Independent Sector Hospitals more than 300 hospitals were contacted on several occasions.  
There were four elements to the project. First, a baseline survey collected retrospective data on 
anaesthetists' previous experiences with perioperative anaphylaxis and their perceptions and 
patterns of risk-avoidance.
9
 Second, UK allergy clinic services were surveyed to identify clinics that 
investigated suspected perioperative anaphylaxis and to compare their practices against 
guidelines.
12
 Third, the main prospective study collected anonymised case reports over a one-year 
period. Fourth, a prospective survey, also in 2015, collected comprehensive information on 
workload, demographics and patients' exposure to potentially-allergenic drugs and other substances 
during anaesthesia and surgery.
13
  
LCs were sent detailed information (available at  http://www.nationalauditprojects.org.uk/NAP6-
Resources#pt) and were tasked with disseminating and co-ordinating all phases of the project 
locally.  
 
All allergy clinics investigating perioperative anaphylaxis were contacted and informed of the 
project. Materials were made available to enable them to give LCs detailed information about tests 
performed and their results when investigating suspected perioperative anaphylaxis. 
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LCs were asked to ensure the reporting of all cases of suspected life-threatening perioperative 
anaphylaxis to the NAP6 team.  Anaphylaxis was defined as a severe, life-threatening, generalized or 
systemic hypersensitivity reaction. Perioperative anaphylaxis was defined as  
 
Anaphylaxis which occurs in patients undergoing a procedure requiring general or 
regional anaesthesia or sedation or managed anaesthesia care (anaesthetist 
monitoring only) under the care of an anaesthetist between the period of first 
administration of a drug (including pre-medication) and the post-procedure transfer 
to the ward, or critical care. 
 
As we only wished to collect cases of life-threatening anaphylaxis it was emphasised that only 
anaphylaxis grades 3-5 (table 1) were to be included.  Cases were to be included irrespective of age 
or hospital location, but patients in critical care or the emergency department were excluded unless 
undergoing procedural general anaesthesia.  
 
(Table 1 near here) 
 
Each month the LC was required to provide the central NAP6 team with a ‘return’ indicating the 
number of reports of suspected life-threatening perioperative anaphylaxis identified that month, 
using a system developed by the UK obstetric surveillance system
14
 and also used in NAP5.
5
 Where 
no reports were received the LCs returned a ‘nil’ report. 
 
Presentations, posters and promotional material were provided to each LC and the project was 
widely advertised nationally (Figure 1). Information provided to LCs included advice on 
interpretation of grades of anaphylaxis and a series of ‘frequently asked questions’, with answers. 
For example, LCs were advised to regard hypotension that was mild or required modest doses of a 
vasopressor or fluid as meeting the definition of Grade 2, whereas hypotension that was profound, 
sustained, resistant to treatment or requiring extensive treatment met the criteria for grade 3.  
 
(Figure 1 near here) 
 
Reporting cases 
Reporting was in two parts.  
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Part A included details of the patient, drugs administered, the clinical features, management and 
timings relating to the event, outcomes, contributory factors, referral for investigation and details of 
reporting of the event and communication to the patient. LCs were to asked submit part A as soon 
as possible after the suspected anaphylactic event. Definitions of clinical features associated with 
anaphylaxis required to be reported were provided in the webpage supporting information 
(Supplementary Table 1). 
 
Part B was to be completed by the LC, after allergy clinic investigation was complete. It included full 
details of allergy clinic investigations, sought to confirm patient outcomes, and to update the data 
on reporting to national registries and information given to patients. Part B was not required fro 
fatalities. 
 
Between them, the two parts of the case reporting form collected detailed information on all 
aspects of the event and patient care. The questions are not reproduced here but are available at 
http://www.nationalauditprojects.org.uk/NAP6-Data-Entry#pt  
 
Cases were included if the event occurred between 00.00 hrs on 5
th
 November 2015 and 23.59.59 
hrs on 4
th
 November 2016. Reports were accepted until May 2017 to allow for allergy clinic waiting 
times. 
Case reporting was confidential. When an LC or other anaesthetist wished to report a case, they 
contacted the NAP6 administrator. The reporter was required to confirm 
 This was a case of suspected perioperative grade 3-5 anaphylaxis, as defined above. 
 The case occurred in the data collection period. 
 Whether the case took place in an NHS or independent sector hospital. 
After confirmation that the case met inclusion criteria, the reporter was issued with a unique 
identifier and password. These were used to submit case details to a password protected, secure 
and encrypted website. Before accessing the webform the LC was required to change their 
password. Cases arising from NHS and independent sector hospitals were assigned different 
numbers for easy identification. No patient, clinician or hospital data was admissible, and the 
webpages repeatedly reminded reporters not to include such information 
 
The NAP6 administrator could track progress of reporting (not started: started but incomplete; 
complete; submitted) but could not access forms. Once completed and submitted the anonymised 
form was automatically transferred electronically to the project clinical lead, who was able to raise 
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queries and receive replies about case reports via a blind email (i.e. he was blinded to where the 
email went to or from where replies came). No other panel members received reports or had access 
to the website. In this manner, no panel member was aware of the geographical origin of any case, 
nor of any individuals involved in managing the case.  
 
A moderator, a consultant anaesthetist with appropriate expertise, was available to discuss cases 
when there was uncertainty about inclusion. The moderator was not on the review panel and had no 
contact with the review panel throughout the project.  
 
Review of cases 
The NAP6 panel met monthly to review and classify cases.  The panel was comprised of 
representatives of patient support groups, patient representatives, and clinicians in relevant fields 
(anaesthesia, critical care, allergy, immunology) representing stakeholder and subspecialty 
organisations. Clinicians were selected by stakeholder organisations and while many had specific 
expertise in allergy, this was not a requirement for joining the panel.  
 
The panel reviewed each case in detail and in a structured manner, three times. First, the clinical 
care (Part A) was reviewed by a small group of 3-5 clinical and patient representative panel 
members. Second, allergists and immunologists reviewed drug administration and allergy 
investigations (relevant parts of Part A and all of Part B). Several groups performed these tasks on 
different cases concurrently. The outputs of the reviews were used to populate a structured output 
form (Appendix 1) and spreadsheet for subsequent analysis. When sufficient cases were reviewed, 
all groups joined into a large panel, of typically 12-15 panel members, and the cases were again 
reviewed to combine the outputs of the clinical and allergy/immunology reviews and to check and 
moderate each small group’s findings.  
This process was used in an attempt to avoid ‘outcome bias’ (where the known poor outcome leads 
to an unreasonably harsh judgement),
15
 ‘hindsight bias’ (where retrospective review leads to a 
tendency to believe that an adverse outcome was predictable or avoidable)
16
 and ‘groupthink’ 
(where a desire to agree within groups leads to a lack of independent scrutiny).
17
   
In judging quality of care, we referred to guidelines from: the Association of Anaesthetists  of Great 
Britain and Ireland on management of suspected anaphylaxis associated with anaesthesia;
18
 the 
Resuscitation Council (UK) on management of anaphylaxis;
19 
 the European Resuscitation Council on 
cardiopulmonary resuscitation;
20
 and the British Society for Allergy and Clinical Immunology (BSACI) 
guidelines on investigation of anaphylaxis during general anaesthesia.
21
 In addition, the review panel 
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referred, where appropriate to NICE CG183 Drug allergy: diagnosis and management of drug allergy 
in adults, children and young people.
22,23
 and NICE CG134 Anaphylaxis: assessment and referral after 
emergency treatment
24 
As these guidelines were used to measure deviation from standards of care, NAP6 had a greater 
genuine ‘audit’ component than previous NAPs. Overall quality of care (initial management, clinic 
referral by anaesthetist and allergy clinic investigation) were also each judged as ‘good’, ‘poor’, 
‘good and poor’ or ‘unassessable’ based on adherence to guidelines and ultimately by panel 
consensus.  
 
It became rapidly apparent that cardiopulmonary resuscitation (CPR) was frequently not started 
when there was profound hypotension. We therefore defined a systolic blood pressure, below which 
we judged that CPR should be started, which we set at 50mmHg (see discussion). These cases were 
classified as grade 4. When CPR was not started, we judged this as failure to initiate CPR when 
indicated and judged this to be a deviation from resuscitation guidelines.  
 
The case report form included specific questions about potential errors related to allergy history or 
administration of cross reacting substances. Preventability of each case was classified as ‘yes’, ‘no’, 
‘uncertain’ and reasons why the event may have been prevented were recorded.  
 
Patient outcomes were measured in two ways. Individual patient outcomes were captured on the 
case report form including new anxiety about future anaesthetics, features consistent with post-
traumatic stress disorder, change in mood, impaired memory, impaired coordination, impaired 
mobility, myocardial infarction, heart failure, renal impairment and stroke. Overall severity of 
patient outcome, was recorded using the National Patient Safety Agency classification of severity of 
harm from patient incidents (Table 2).
25
 In most cases Grade 3 anaphylaxis itself meets the definition 
of moderate harm. When resuscitation had only involved minimal doses of vasopressor or other 
drugs and no further action taken the case was deemed to meet the criteria for minimal harm. 
Apparently permanent sequelae (i.e. persisting symptoms or deficits at follow-up) were recorded as 
severe harm, as were cardiac arrest and ICU stay >14 days.  
 
(Table 2 near here) 
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Each event was classified as ‘allergic anaphylaxis’, ‘non-allergic anaphylaxis’, ‘anaphylaxis mechanism 
uncertain’, ‘anaphylaxis uncertain’ or ‘not anaphylaxis’ using the classification shown in Table 3. For 
each classification certainty of classification was recorded as high or intermediate.   
 (Table 3 near here) 
In order to classify the type of each event, a definition of mediator release was required. Providing 
mast cell tryptase samples were taken at appropriate times after the event (broadly: soon after the 
event and approximately 1-3 hours after the event and a baseline sample either taken before the 
event or ≥24 hours after the event) the following definition was used: 
 
 Peak mast cell tryptase ≥1.2x nadir value + 2µg.L
-1
 
26 
or 
 Peak mast cell tryptase ≥14 µg.L
-1
 (i.e. >99
th
 centile for normal mast cell tryptase levels)
27
 
 
This was a pragmatic definition and made in the knowledge that the second part of the definition 
might not fully exclude a very small number of cases of mastocytosis.  
 
Where there was uncertainty, differential diagnoses other than anaphylaxis were carefully 
considered by both clinicians and allergist/immunologists. 
In determining adequacy of allergy clinic investigation, BSACI guidelines
21, 28,29
 were used by the 
immunologists and allergists to set the following rules.  
 
 Where testing for allergy to neuromuscular blocking agent (NMBA) was necessary, given 
variable access to some NMBA the NAP6 minimum panel
12
 was applied: suxamethonium, 
rocuronium and either atracurium or cis-atracurium should have been tested and at least one 
safe alternative should have been sought. 
 Chlorhexidine and latex should have been investigated routinely because of the widespread risk 
of exposure. 
 For SPTs and intradermal tests (IDTs) to be judged appropriate, there should be no tests 
performed that were not indicated. This was to exclude ‘scatter-gun’ testing being judged as 
good practice. 
 Allergy to antibiotics and particularly beta-lactams could only be excluded if a negative skin test 
was followed by negative provocation testing 
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The allergists and immunologists reviewed each case that was confirmed to be anaphylaxis, to 
determine all possible causative agents (culprits). Reviewing the clinical data and allergy clinical 
tests, they identified these drugs as having high, intermediate or low culpability.  
We recorded ‘identified culprits’ as follows  
 
 Definite: where one sole agent was recorded with a high degree of confidence and any other 
agents with intermediate or low confidence. 
 Probable: (a) where only one agent was recorded with an intermediate degree of confidence 
and any other agent was identified with low confidence (b) where two agents were both 
recorded with a high degree of confidence.  
 Possible: where two agents were recorded with an intermediate degree of confidence and none 
with a high degree of confidence.  
 Do not count: (a) where more than two agents were recorded with a high degree of confidence 
(b) where more than two agents were recorded with an intermediate degree of confidence (c) 
where the only agents recorded were identified with a low degree of confidence. 
 
Agents meeting the criteria for definite or probable were considered to be ‘identified culprits’: 
agents meeting the criteria for possible or do not count, were not. 
 
Approximately 10-12 cases were fully reviewed each day in the early part of the review process, 
increasing to up to 22 in the latter stages as the panel became more familiar with the process. Due 
to the high number of cases submitted we were not able to perform full reviews of all cases. The 
remaining cases in the main dataset had a limited review that determined: the diagnosis of 
anaphylaxis, the grade of anaphylaxis, all potential culprits and ‘identified culprits’. 
 
Results 
The results of the Allergy clinic survey,
9
 Anaesthesia Baseline survey,
12
 Anaesthetic Activity survey
30
 
and Allergen survey
13
 are each reported separately and are not considered further here. There were 
no technical or security breaches of the website, or concerns about identification of patients, 
clinicians or hospitals.  
 
All 356 (100%) NHS hospitals where surgery was undertaken agreed to take part in the project and 
volunteered an LC. These 356 hospitals were served by 282 LCs. Eighty four percent of NHS hospitals 
returned all monthly reports: overall return rate of ‘monthly reports’ from NHS hospitals was 94%. 
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Responses were considerably fewer from independent sector hospitals. In total 41 (13%) 
independent sector hospitals volunteered to participate and these hospitals were included in data 
collection. Thirty nine percent of these independent sector hospitals returned all monthly reports: 
overall return rate of ‘monthly reports’ from these independent sector hospitals was 70%. 
In view of the small number of independent sector hospitals that agreed to participate it was 
decided that this sample would not be representative of practices or events in this healthcare sector 
and a decision was made to include their data only for examination of isolated events and not for 
numerical analysis. 
The full results of analysis and findings of reports of anaphylaxis are presented in the accompanying 
papers.
31,32
 We present here the results of the NAP6 process.  
 
There were 628 requests made for login details to the reporting website. A total of 541 cases were 
submitted: 412 with part A and part B completed, 125 with only part A completed and four with only 
part B completed. Amongst these there were seven requests for an identifier for the reporting 
website from independent sector hospitals but only two cases were fully reported. These cases were 
not included in the main dataset. 
 
Only those cases with part A and part B (n=256), or deaths (n=10) were considered for review. Of 
these 93 were not suitable for review due to lack of detail or not meeting entry criteria; 27 were 
uninterpretable; 15 were not anaphylaxis; nine were excluded as being grade 2 anaphylaxis: two 
were from independent sector hospitals.  
 
A total of 266 NHS cases met inclusion criteria, were interpretable and were grade 3-5 anaphylaxis: 
these formed the main dataset. 
 
A total of 217 cases were fully reviewed, including 184 of the main dataset. The remaining 82 cases 
underwent limited review, as described above.  
 
Amongst the 266 cases in the main dataset, there was an identified culprit in 192 cases. In seven 
cases there were two identified culprits (all because two agents were identified with high 
confidence) so the total number of identified culprits was 199 (Table 4).  
 
(Table 4 near here) 
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Discussion 
NAP6 is likely to be the most comprehensive prospective study of perioperative anaphylaxis ever 
undertaken. It provides prospective data on a large number of cases which have all been subject to 
structured multidisciplinary expert review. It provides the opportunity to learn about preparedness 
of hospitals and clinicians, clinical presentation of perioperative anaphylaxis, severity, immediate 
management, referral for investigation, and outcomes. It provides significant epidemiological data 
about distribution of anaphylaxis grade, suspected and actual triggers, and non-standard 
treatments. Further, it provides data on the quality of management and investigation in a ‘real world 
setting’ and of communication, between clinicians and to patients.  
In order to collect and analyse this data in a meaningful manner it was important to perform a 
structured analysis of cases. That structure was underpinned by clear definitions of which events 
should be included or excluded and also by classification during review. We followed the review 
process previously used in other NAPs which included multiple, serial, multidisciplinary reviews 
incorporating patient representation, formal moderation and a structured output. Review of events 
that have already happened is always prone to the limitations of ’looking backwards’ and this may 
be exacerbated when the outcome of the event is known.
15-17
 Our processes made every effort to 
produce balanced judgements, accepting these known limitations.  
Anaphylaxis is ‘a severe, life-threatening generalised hypersensitivity reaction.’
33  
Lesser 
hypersensitivity reactions should not be included in the term anaphylaxis. Unlike many previous 
large-scale studies of hypersensitivity we have focussed only on genuinely life-threatening reactions 
(i.e. true anaphylaxis). We judged this would enable us to gather the most clinically powerful 
lessons, to improve engagement in the project and to increase capture rates. These are also the 
cases where most is to be gained (or lost) in efforts to improve care.  
 
There are numerous gradings scales and definitions of severity of hypersensitivity/anaphylaxis and 
the cut-offs between grades vary considerably. This has implications for data analysis and 
comparisons between studies. Ring and Messmer’s 1977 classification included four grades with 
grade 3 ‘shock, life-threatening spasm of smooth muscles (bronchi, uterus etc)' grade 4 'cardiac 
and/or respiratory arrest'.
34
 Garvey in 2001 described only three grades with the highest grade 
(grade 3) including all ‘Very severe reactions requiring prolonged treatment, e.g. anaphylactic shock, 
usually, but not always, involving two or more organ systems’.
35
 Mertes in 2003 included in grade 3 
life threatening events ‘cardiovascular collapse, tachycardia or bradycardia, arrhythmias, severe 
bronchospasm’ and in grade 4 ‘circulatory inefficacy, cardiac and/or respiratory’.
36
 In 2007 Kroigaard 
introduced grade 5: fatal anaphylaxis.
37
 Consensus diagnostic criteria for definition of anaphylaxis 
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was reported in 2006 but have significant limitations if applied to perioperative anaphylaxis.
38
 In 
2010 yet another classification was published - classifying all hypotension as grade 4.
39 
 
Despite this apparent surfeit of grading systems, we found none entirely clear or satisfactory and 
developed the classification shown in table 1. This classification aimed specifically to accommodate 
the normal variations in vital signs and physiology that can be seen in the perioperative setting, 
particularly in elderly, frail or co-morbid patients.  The NAP6 classification of perioperative 
(hypersensitivity and) anaphylaxis uses the pragmatic terms ‘unexpected’ and ‘severe’ in the belief 
that anaesthetists can distinguish the usual from the unusual, and a reaction requiring rescue 
treatment from one which does not. We used a clear cut off for grade 4 i.e. if indications for 
initiating CPR are fulfilled. During the NAP6 project another group published a new classification and 
this also usefully reviews many of the existing classifications and their limitations in respect to 
perioperative anaphylaxis.
40
 This used three grades A-C: grade A is non life-threatening and 
therefore does not meet the accepted definition of anaphylaxis and grade B includes some grade 2-3 
characteristics of other groups, grade C being similar to Kroigaard’s grade 4.   
During early case reviews it became apparent that ‘indication for CPR’ might not be as clear-cut as 
we had thought. The case report form asked both for the lowest blood pressure recorded and 
whether CPR was started. In a large number of cases the lowest blood pressure was very low, often 
being <60mmHg or <50mmHg or even unrecordable, but CPR was not performed. This was discussed 
at length in the panel. We took external expert advice, from experts in resuscitation, anaphylaxis and 
their guidelines and concluded that, it was logical to set a lowest systolic blood pressure at which it 
was reasonable that CPR should start, in adult patients. In the awake patient it is now routine to 
start CPR when ‘there are no signs of life/signs of responsiveness’. As perioperative anaphylaxis most 
commonly takes place after induction of anaesthesia, these signs are absent. In invasively monitored 
patients a blood pressure of <50mmHg is predictive of central and peripheral pulselessness
41
 which 
should trigger CPR. As non-invasive blood pressure monitors tend to over-estimate the blood 
pressure in severe hypotension, a non-invasive blood pressure recording of <50mmHg implies the 
true blood pressure is even lower. We therefore judged that when the lowest systolic blood pressure 
was <50mmHg, CPR was indicated. This rule was then applied to all cases. These cases were 
recorded as grade 4, and if CPR was not started recorded as ‘CPR not started when indicated’. We 
also judged this a deviation from (resuscitation) guidelines and recorded whether this was the only 
such deviation. This group of patients (lowest systolic blood pressure and no CPR) were examined as 
a separate cohort to explore whether their outcomes differed from other patient groups.
27
 The 
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NAP6 classification of grade of anaphylaxis was therefore updated to include this critical blood 
pressure cut-off (Supplementary table 2).  
In the analysis of investigation of anaphylaxis the allergists and immunologists on the panel required 
a clear way to classify the type of immunological event and devised that shown in Table 3. The 
presence of a dynamic tryptase rise was determined using an accepted consensus method,
26
 which 
has (since NAP6 started) been confirmed to have high specificity (78%), positive predictive value 
(98%) and a moderate negative predictive value (44%) in perioperative anaphylaxis.
42
 Where there 
was no dynamic rise in tryptase we used a value of >99
th
 centile as indicating elevation: this has been 
shown to improve sensitivity of the above test.
27
 This goes well beyond previous reports which have 
often simply classified cases as ‘IgE mediated – hypersensitivity with skin prick test positive; non IgE-
mediated – hypersensitivity with skin prick test negative, or unclassified’. Assessing utility and quality 
of allergy clinic investigation was further aided by including the consensus view that the NAP6 panel 
of NMBAs
12
 should be used and that allergy to both chlorhexidine and latex allergy should be tested 
routinely because of their widespread (and often hidden) presence in healthcare settings.
12,21, 43,44
  
Finally we used a structured method to define the degree of certainty with which culprit agents were 
identified and only included those that were definite or probable culprits in reporting our findings. 
The published guidelines selected for providing standards against which the quality of practice was 
assessed
18-22
 were chosen to encompass immediate resuscitation (including of cardiac arrest), 
secondary clinical management, referral to an allergy clinic, primary and specialist allergy 
investigation, record keeping, and communication with patients and healthcare professionals. 
United Kingdom guidelines were selected, being the most relevant to the patient population being 
studied. 
 
Using this method, we received >500 reports of perioperative anaphylaxis. We were able to analyse 
266 cases and identify 199 culprit agents in 192 cases. Our findings include the important 
observations that: antibiotics (47%) are a more common cause of perioperative anaphylaxis than 
neuromuscular blocking drugs (33%); chlorhexidine (9%) and patent blue dye (4.5%) were prominent 
triggers; latex was not (0%). These findings are discussed in context and full numerical analysis in the 
accompanying paper
28
 and in the full report.
 
As with previous NAPs, NAP6 is the product of a concerted national effort by all departments of 
anaesthesia in the UK and through its various phases the vast majority of UK anaesthetists. This 
project has also involved considerable multidisciplinary working with both allergists and 
immunologists. The project could not take place without the generous voluntary efforts of many 
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people and we acknowledge that here and offer them our thanks.  The projects require 
anaesthetists to report cases where a significant critical incident has occurred, and harm may have 
come to the patient. We rely on anaesthetist’s openness and honesty. The NAP6 panel, including the 
Clinical Lead, had no access to any information regarding the geographical source of the report, the 
identity of the reporter, or any patient, hospital or clinician identifiable details. This anonymity, 
provided within the project design remains central to its success.  
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Table 1. Grading of perioperative hypersensitivity/anaphylaxis used for determining inclusion or 
exclusion in the NAP6 project.  
 
Grade Features  NAP6 
1 Not life-
threatening 
Rash, erythema and/ or swelling Hypersensitivity - 
Excluded 
2 Not life-
threatening 
Unexpected hypotension – not severe e.g. not 
requiring treatment 
and/or bronchospasm –  not severe e.g. not requiring 
treatment  
+/- Grade 1 features 
Hypersensitivity - 
Excluded 
3 Life-threatening Unexpected severe hypotension  
and/or severe bronchospasm 
and/ or swelling with actual or potential airway 
compromise 
+/- Grade 1 features 
Included if 
perioperative 
anaphylaxis 
suspected.  
 
4 Life-threatening Fulfilling indications for CPR Included if 
perioperative 
anaphylaxis 
suspected.  
 
5 Fatal Fatal Included if 
perioperative 
anaphylaxis 
suspected.  
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Table 2. Degree of physical harm. Source: NPSA Seven steps to patient safety23 
Severity 
grade  
Description (tick against the most severe feature) 
Uncertain Insufficient information  
Mild Minimal harm necessitating extra observation or minor treatment* 
Moderate Significant, but not permanent harm, or moderate increase in treatment** Includes  
delayed cancer surgery (Q 27.9) 
Severe Permanent harm due to the incident***, Also including cardiac arrest (Q 14.1); 
adverse sequelae recorded as “Severe” in Part A (page 26) or Part B (page 4,5); ICU 
stay of 14 days or long r (Q 23.8) 
Death Death due to the incident 
* first aid, additional therapy or additional medication. Excludes extra stay in hospital, return to 
surgery or readmission. 
** return to surgery, unplanned re-admission, prolonged episode of care as in or out patient or 
transfer to another area such as intensive care. 
*** permanent lessening of bodily functions, sensory, motor, physiologic or intellectual. 
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 Table 3 Immunological classification of events in NAP6 
Class of event 
In addition to history 
of reaction grade 3,4,5  
High certainty  Intermediate certainty 
Allergic anaphylaxis  
(IgE-mediated) 
Timeline – within 60 min 
Evidence of mast cell mediator 
release -tryptase  
Evidence of positive sIgE (blood or 
skin tests)* 
Differential diagnoses excluded  
 
4/4 criteria; *essential 
Timeline - within 60 min 
Evidence of mast cell mediator 
release -tryptase  
Evidence of positive sIgE (blood 
or skin tests)* 
Differential diagnoses excluded  
 
3/4 criteria; *essential 
Non-allergic 
anaphylaxis 
(non IgE-mediated) 
Timeline – within 60 min 
Evidence of mast cell mediator 
release -tryptase (see note 2) 
No evidence of positive sIgE (blood 
or skin tests) 
Differential diagnoses excluded  
 
4/4 criteria 
Timeline – within 60 min 
Evidence of mast cell mediator 
release -tryptase  
No evidence of positive sIgE 
(blood or skin tests) 
Differential diagnoses excluded  
 
3/4 criteria 
Anaphylaxis – 
mechanism uncertain 
Timeline – within 60 min 
Evidence of mast cell mediator 
release -tryptase  
Skin tests or blood sIgE not 
available 
 
3/3 criteria 
 
Anaphylaxis uncertain  Meeting 2/3 criteria in 3 above 
and/or 
Differential diagnoses more likely: 
Airway management 
Drug side effect 
Drug overdose 
Cardiac disease/event 
 
 
Not anaphylaxis Not meeting clinical criteria for 
diagnosis (as per grading) 
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Table 4. The 199 identified culprit agents in 193 cases of anaphylaxis in NAP6. 
Drugs by class 
                                         Definite                          Probable                                Total 
Antibiotics 67 27 94 
NMBA 49 16 65 
Chlorhexidine 14 4 18 
Patent blue 8 1 9 
Others 10 3 13 
  
   All 148 51 199 
Antibiotics 
    
Co-amoxiclav 38 8 46 
Teicoplanin 21 15 36 
Cefuroxime 2 2 4 
Gentamicin 1 2 3 
Flucloxacillin 2 0 2 
Tazocin 1 0 1 
Vancomycin 1 0 1 
Metronidizole 1 0 1 
 NMBAs 
 
  
 
Rocuronium  21 6 27 
Atracurium 14 9 23 
Suxamethonium 13 1 14 
Mivacurium 1 0 1 
 
Antiseptics and Dyes 
 
Chlorhexidine 
Patent blue 
 
14 
8 
 
4 
1 
 
18 
9 
Other agents 
 
  
 
Gelatin 3 0 3 
Blood products 2 0 2 
Ondansetron 1 1 2 
Sugammadex 
Ibuprofen 
1 
1 
0 
0 
1 
1 
Propofol 1 0 1 
Protamine 1 0 1 
Aprotinin 0 1 1 
Enoxaparin 0 1 1 
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Figure 1. Supporting information on which cases should be reported to NAP6. 
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Appendix 1. Panel review form. 
DATE OF REVIEW:    CASE ID: 
 
Does the report meet the inclusion criteria?     Yes    No 
If no, why: 
 
 
Might it be a duplicate?     Yes    No 
If yes, action taken: 
 
 
Is the report interpretable?     Yes    No 
If no, action taken: 
 
 
Timing of event ("induction" refers to first drug/substance administered by the anaesthetist) 
  Pre-induction          After induction and before surgery/intervention   
  During surgery/intervention      After completion of surgery/intervention 
 
Class of event (as determined by review panel) 
  Allergic anaphylaxis    Non-Allergic anaphylaxis    Anaphylaxis, mechanism uncertain   
  Not anaphylaxis    Uncertain    Not stated   
 
Class of event (as determined by allergy clinic) 
  Allergic anaphylaxis    Non-Allergic anaphylaxis    Anaphylaxis, mechanism uncertain   
  Not anaphylaxis    Uncertain    Not stated   
 
Grade of event as determined by review panel:     1    2    3    4    5    Uncertain 
 
Immediate care (tick) 
 Yes No Unclear N/A 
Resuscitation by anaesthetist of appropriate grade     
Prompt recognition of critical event     
Prompt recognition of anaphylaxis     
Appropriate airway management     
Prompt pharmacological treatment for anaphylaxis     
Comprehensive pharmacological treatment for anaphylaxis     
Prompt initiation of cardiac compressions     
Administration of adrenaline when indicated     
Appropriate iv fluid management     
Suspected culprit agent discontinued promptly     
Actual culprit agent discontinued promptly     
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Intervention abandoned appropriately     
 
Clinical management by the anaesthetist: 
  Good    Poor    Good and poor elements     Un-assessable 
 
Subsequent care (tick) 
 Yes No Unclear N/A 
Transfer to different hospital for HDU/ICU     
Written information given to patient prior to clinic appointment     
Appropriate MCT samples requested     
Appropriate MCT results available     
Investigation impacted by un-actioned MCT sample request(s)?     
Was the patient referred to an allergy clinic if appropriate?     
Was adequate information provided to the allergy clinic at referral?     
Was the clinic waiting time significantly detrimental to the patient?     
Patient given written information by anaesthetist prior to clinic 
appointment 
    
Patient given hazard warning e.g., Medic Alert by anaesthetist     
Case reported to MHRA by anaesthetist     
 
Referral to allergy clinic: 
  Good    Poor    Good and poor elements     Un-assessable 
 
Allergy clinic investigation (tick) 
 Yes No Unclear N/A if no specify 
All potential culprits investigated      
Sufficient panel of muscle relaxants*      
Chlorhexidine investigated*      
Latex investigated*      
Appropriate SPTs*      
Appropriate IDTs*      
Appropriate blood tests      
Was it necessary to measure baseline MCT in 
clinic 
     
Appropriate challenge tests 
 
     
Appropriate advice on future avoidance      
Written information to patient e.g. copy of 
clinic letter 
     
Clinic letter to anaesthetist      
Clinic letter to GP      
Patient given Hazard Warning e.g. Medic Alert 
by clinic 
     
Case reported to MHRA by clinic      
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* see crib sheet 
 
Allergy clinic investigation: 
  Good    Poor    Good and poor elements     Un-assessable 
 
Culprit agent(s) 
Identity of 
drugs/substance 
suspected by: 
Drug/substance 
1 
Certainty 
H/I/L/Not 
stated 
Drug/substance 
2 
Certainty 
H/I/L/Not 
stated 
Unable 
to 
identify 
(tick) 
Not 
recorded 
(tick) 
Anaesthetist       
Allergy clinic       
Review panel       
 
CONTRIBUTORY AND CASUAL FACTORS 
Specific (tick those that apply) 
 Yes No Unclear N/A 
Incomplete pre-intervention allergy history     
Pre-intervention allergy history not heeded     
Possibility of cross-sensitivity not heeded     
A previous reaction was not appropriately investigated     
 
Was the index event preventable?     Yes    No    Uncertain 
 
If yes, how might it have been prevented? 
 
 
If there was a further reaction, could it have been prevented? 
   Yes    No    Uncertain    N/A 
 
If yes, how might it have been prevented? 
 
 
SEVERITY OF PHYSICAL HARM (NPSA) 
This is the harm occasioned by the whole episode (see crib sheet) 
Severity grade Description (tick against the most severe feature) Tick 
Uncertain Insufficient information  
None No harm (whether lack of harm was due to prevention or not)  
Low Minimal harm necessitating extra observation or minor treatment  
Moderate Significant, but not permanent harm, or moderate increase in treatment  
Severe Permanent harm due to the incident  
Death Death due to incident  
 
Page 28 of 28British Journal of Anaesthesia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
28 
 
DEPARTURE FROM GUIDELINES 
Significant departure from: Unclear N/A Yes No If yes specify 
AAGBI Safety Guidelines      
RCUK Guideline      
BSACI Guideline on investigation      
 
Lessons to be learned: 
 
 
Any possible recommendations arising: 
 
 
Amend Summary Narrative (i.e. modify draft prepared by NH)    Yes    No 
Action taken: 
 
 
Consider: Any further information needed. If yes, action taken: 
 
 
Is this case suitable for a vignette?     Yes    No. If yes, why? 
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